Epigenome, Microbiome, and Metabolites: Unraveling the Complex Pathogenesis of Celiac Disease
Litsenziya: other-oa
Annotatsiya
Celiac disease (CeD) is a chronic autoimmune disease triggered by gluten consumption in genetically susceptible individuals, primarily those with HLA-DQ2 or HLA-DQ8 haplotypes. Although these genetic factors are responsible for a substantial portion of disease risk, they do not fully explain disease heritability or the rising incidence observed worldwide. Recent clinical studies highlight epigenetic modifications-including DNA methylation, histone modifications, non-coding RNA regulation, and RNA methylation-as critical mediators bridging genetic susceptibility and environmental influences, such as gut microbiota dysbiosis, dietary patterns, early-life exposures, infections, and pharmaceutical interventions. These epigenetic mechanisms modulate immune responses, intestinal barrier function, and inflammatory pathways, contributing to the loss of gluten tolerance and perpetuation of mucosal damage. Key players, including tissue transglutaminase 2 (TG2) and interferon-gamma (IFN-γ), form amplifying feedback loops that exacerbate pathogenesis. Bacterial metabolites and lifestyle factors further influence epigenetic landscapes, offering reversible targets for intervention. This review synthesizes current evidence on epigenetic alterations in CeD, emphasizing their interplay with microbiota and metabolites, tissue-specific patterns, and potential as biomarkers. It also explores implications for novel therapeutic strategies beyond the gluten-free diet, including epigenetic modulators and microbiota-targeted approaches, to advance personalized prevention and management of CeD.
Hali tarjima qilinmagan